Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small G protein signaling modulator 3 (SGSM3) is a multi-domain adapter protein classified within the RUN and TBC1 domain-containing family, functioning primarily as a modulator of small G protein signaling pathways involving RAP and RAB subfamilies[1][2]. It interacts with connexin 43 (Cx43), a key gap junction protein, modulating its turnover and cellular localization, and thereby participating in the regulation of cell–cell communication, apoptosis, and cell differentiation, notably in cardiac and stem cell contexts[1]. Variants in SGSM3 have been associated with autism spectrum disorders and various cancers[1][2]. The protein is expressed in multiple tissues including the central nervous system, and while mechanistic and drug interaction data remain limited, it is regarded as a potentially important modulator of cell signaling and survival, with roles emerging in cardiac biology, neurodevelopment, and tumorigenesis[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small G protein signaling modulator 3 (SGSM3).